Bli medlem
Bli medlem

Du är här


MorphoSys AG: Annual General Meeting of MorphoSys AG Approves All Proposals of the Company's Management

MorphoSys AG / Annual General Meeting of MorphoSys AG Approves All Proposals
of the Company'sManagement . Processed and transmitted by NASDAQ OMX
Corporate Solutions.The issuer is solely responsible for the content of this
Dr. Walter Blättler re-elected as Supervisory Board Member

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
at the Company's Annual General Meeting on Friday, 23 May 2014, its
shareholders approved all proposals of the Company's Management put to vote
at the meeting including:

* The carrying forward of the accumulated profit of the 2013 financial year.
* The formal approval of the activities of the members of the Management and
Supervisory Boards in respect of the 2013 financial year.
* The appointment of PricewaterhouseCoopers AG as auditor of MorphoSys AG and
the MorphoSys Group for the 2014 financial year.
* The creation of a new Authorized Capital 2014-I with the possibility to
exclude pre-emptive rights of the shareholders.
* The re-election of Dr. Walter Blättler as a member of the Supervisory Board
for one additional year.
* The authorization to purchase treasury shares pursuant to Section 71 para.
1 no. 8 of the German Stock Corporation Act and to use treasury shares with
the possibility to exclude pre-emptive rights of the shareholders.

"We are pleased to announce the re-election of Walter Blättler, an experienced
member of the Supervisory Board with many years of experience in the
development of antibody-based cancer drugs, and look forward to continue
working with him," commented Dr. Simon Moroney, Chief Executive Officer of
MorphoSys AG.

At the Annual General Meeting 2014 of MorphoSys AG, 47.81 % of the voting
shares were represented.
More information on the Company's Annual General Meeting including the voting
results on all agenda points can be found on

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 80 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Specialist Corporate Communications&IR

Jessica Rush
Specialist Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404

Medie Release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.